Physician profile
Danielle Andry
NPI 1215295621
$28,327.27
in general payments reported to CMS, 2019-2025
27 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,134 · 2020: $476 · 2021: $782 · 2022: $1,324 · 2023: $872 · 2024: $1,062 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $3,681 · Travel and Lodging: $2,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,385.00 |
| Food and Beverage | $3,680.72 |
| Travel and Lodging | $2,545.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,171.04 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Allergan, INC. | $4,851.59 | 2019-2022 | |
| Sientra, INC. | $1,132.83 | 2019-2022 | |
| Revance Therapeutics, INC. | $1,095.77 | 2024-2025 | Daxxify, Daxi |
| Mentor Worldwide LLC | $531.84 | 2019-2023 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Surgical Innovation Associates, INC. | $320.17 | 2022 | |
| Merz North America, INC. | $238.33 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $228.52 | 2022-2024 | Dupixent |
| Galderma Laboratories, L.P. | $219.32 | 2019-2024 | |
| Kci USA, INC. | $216.16 | 2019 | |
| Axogen | $199.28 | 2019-2022 | |
| Integra Lifesciences Corporation | $167.81 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Alafair Biosciences, INC. | $144.47 | 2023 | Versawrap |
| Incyte Corporation | $130.49 | 2022-2025 | Opzelura |
| Musculoskeletal Transplant Foundation INC. | $100.21 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $95.26 | 2023-2025 | Adbry |
| Bard Peripheral Vascular, INC. | $89.28 | 2021 | |
| Sun Pharmaceutical Industries INC. | $86.05 | 2024-2025 | |
| Medtronic, INC. | $75.98 | 2024 | V-Loc 180 |
| Ucb, INC. | $62.94 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $44.50 | 2024-2025 | Tremfya |
| Vertex Pharmaceuticals Incorporated | $27.10 | 2024 | |
| Lilly USA, LLC | $24.09 | 2024 | Taltz |
| Tela Bio, INC. | $22.31 | 2024 | Ovitex 2s |
| Journey Medical Corporation | $21.97 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.13 | 2023 | Jublia |
| Solta Medical, A Division of Bausch Health US, LLC | $14.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Andry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.